Genotype‐phenotype correlation of unusual BCR‐ABL1 transcripts in Philadelphia chromosome‐positive leukaemia
Open Access
- 1 April 2020
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 189 (5), E207-E211
- https://doi.org/10.1111/bjh.16627
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experienceJournal of Hematology & Oncology, 2019
- Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndromeLaboratory Investigation, 2018
- Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemiaBlood Cancer Journal, 2017
- Impact of complete molecular response on survival in patients with Philadelphia chromosome–positive acute lymphoblastic leukemiaBlood, 2016
- Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemiaBlood, 2011
- Chronic myeloid leukemia with an e13a3 BCR‐ABL fusion: Benign course responsive to imatinib with an RT‐PCR advisoryAmerican Journal of Hematology, 2004
- Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR‐ABL transcript having a DNA breakpoint between ABL exons a2 and a3American Journal of Hematology, 2003
- The molecular biology of chronic myeloid leukemiaBlood, 2000
- Signal Transducer and Activator of Transcription (STAT)5 Activation by BCR/ABL Is Dependent on Intact Src Homology (SH)3 and SH2 Domains of BCR/ABL and Is Required for LeukemogenesisThe Journal of Experimental Medicine, 1999
- The SH3 Domain Contributes to BCR/ABL-Dependent Leukemogenesis In Vivo: Role in Adhesion, Invasion, and HomingBlood, 1998